Cellectricon, Neurexpert Announce Collaboration
News Jun 08, 2016
“As a provider of specialist neurophysiology expertise and with over 80 years combined experience in developing electrophysiological assays to test the action of novel compounds on neuronal synaptic function, we are very excited about this collaboration with Cellectricon,” said Neurexpert co-founder Professor Tom Salt. “With our extensive CNS expertise, we believe that we provide important domain knowledge that adds further value to Cellectricon’s proprietary Cellaxess® Elektra Discovery Services screening platform and expert scientific staff”.
“Through our collaboration with Neurexpert, we have further enhanced our Discovery Services offering for CNS research”, said Cellectricon’s VP Commercial & Technology, Mattias Karlsson. “The additional range of complementary cell-based assays that bridge the gap between in vitro and in vivo screens provides assurance that potency and selectivity data translate into physiologically-relevant activity, thereby confirming mechanism of action. Being able to access the information-rich assays and specialist expertise of the Neurexpert team gives essential functional and mechanistic validation to complement and expand our Discovery Services techniques – a real value-add for our clients”.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE